BRIEF—Enamine and Lundbeck work together on drug discovery

Ukranian drug discovery services firm Enamine has agreed terms for a deal with CNS specialist Lundbeck for an expansion of an existing research collaboration.

Enamine will help with Lundbeck’s in-house discovery efforts with three principal assets, leveraging a diverse library of 100,000 new screening compounds.

Lundbeck’s head of medicinal chemistry Paul Kilburn said: “Enamine’s REAL Database is allowing us to expedite our hit explosion programs at unmatched speed and synthesis success. We look forward to the results of our HTS campaigns and to continue receiving highly valuable compounds exclusively synthesized for us.”